Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this holiday weekend, make sure you’re still in the know with MassDevice +7 and Happy Holidays from everyone at MassDevice!
7. Chinese price controls will hurt U.S. companies, says Lugar
Sen. Dick Lugar (R-Ind.), the head Republican on the Senate’s Foreign Affairs Committee, warned Chinese officials that its proposed price controls for medical products would hurt American companies and Chinese patients.
Sign up to get our free newsletters delivered right to your inbox.
6. IRS wants Medtronic to pay $958M tax tab
Medtronic Inc. (NYSE:MDT) is under the spotlight at the IRS for profit-shifting practices that effectively cut its corporate tax rate in half.
5. Another Maryland doc charged with over-stenting
A malpractice lawyer accused Union Memorial Hospital cardiologist Dr. John Chung-Yee Wang, a member of the committee charged with stopping over-stenting in the Old Line State, of improper stenting in his own practice.
4. FDA requires BSX to include stent “shrinkage” risk in label
Boston Scientific Corp. (NYSE:BSX) must include the potential for stent "shrinkage" in the labeling for its newly cleared Promus Element drug-eluting stent.
3. Covidien lands CE Mark for Nellcor patient monitoring system
Covidien (NYSE:COV) landed CE Mark approval in the European Union for its Nellcor system used to help doctors detect early warning signs of respiratory complications in patients.
2. Judge overturns Smith & Nephew’s $85M patent win over Arthrex
Smith & Nephew (NYSE:SNN) saw its $85 million patent win against Arthrex Inc. overturned this week, after an Oregon judge ruled that Arthrex didn’t infringe on SNN’s surgical anchor patents.
1. Meelia says goodbye to Covidien
Former Covidien (NYSE:COV) president & CEO Richard Meelia decided not to stand for re-election as chairman of the med-tech maker’s board. Due to the smooth executive transition by new CEO Joe Almeida, Meelia decided to retire from the board before the end of the 1-year period, according to an SEC filing.
